Collegium Pharmaceutical, Inc.
COLL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.40 | -0.07 | 0.23 | 0.06 |
| FCF Yield | 21.99% | 26.41% | 15.62% | 15.57% |
| EV / EBITDA | 5.01 | 4.78 | 7.62 | 8.38 |
| Quality | ||||
| ROIC | 9.78% | 12.21% | 3.19% | -80.93% |
| Gross Margin | 59.76% | 57.55% | 45.15% | 54.40% |
| Cash Conversion Ratio | 2.96 | 5.71 | -4.97 | 1.45 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.82% | 26.97% | 14.38% | 6,517,548.29% |
| Free Cash Flow Growth | -25.87% | 123.71% | 20.66% | 136.31% |
| Safety | ||||
| Net Debt / EBITDA | 2.31 | 1.41 | 3.09 | 0.84 |
| Interest Coverage | 2.30 | 2.00 | 0.53 | 0.84 |
| Efficiency | ||||
| Inventory Turnover | 7.15 | 7.44 | 5.47 | 7.26 |
| Cash Conversion Cycle | 177.53 | 151.48 | 205.76 | 177.71 |